ASCO GU 2023 Conference Coverage


 

ASCO GU 2023 Real-World Evidence From Four High-Volume Institutions: Characteristics of Long-Term Responder Patients Treated With Androgen-Receptor Signaling Inhibitors as a 1L Treatment for mCRPC

42 views
February 28, 2023
Comments 0
Login to view comments. Click here to Login